Protection against oxaliplatin acute neurosensory toxicity by venlafaxine.
Venlafaxine (Effexor; Wyeth Lederlé) has previously shown therapeutic effects for the management of chronic and neuropathic pains. We report here the efficacy of venlafaxine upon acute neurosensory symptoms secondary to oxaliplatin toxicity. A dose of 50 mg of venlafaxine was given orally at the beginning of the oxaliplatin infusion. Patients did not experience any or very low paresthesias, even in the cold. As the results were very dramatic and reproducible, we propose that venlafaxine may be of use in the daily management of oxaliplatin-related neurosensory toxicity.
Durand
Jean-Philippe
JP
Unité d'Oncologie Médicale, Service de Médecine Interne 1, Groupe Hospitalier Cochin, Paris, France.
Brezault
Catherine
C
Goldwasser
François
F
D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D003110:Colonic Neoplasms / Q000188:drug therapy*; D003511:Cyclohexanols / Q000494:pharmacology*; D006801:Humans; D008297:Male; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D000077150:Oxaliplatin; D010292:Paresthesia / Q000139:chemically induced* / Q000517:prevention & control; D000069470:Venlafaxine Hydrochloride
D018687:Antidepressive Agents, Second-Generation; D000970:Antineoplastic Agents; D003511:Cyclohexanols; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D000069470:Venlafaxine Hydrochloride